MedTrace Logo

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

NCT02135536 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-03-28

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability, and activity of extended treatment with NGM282 in patients with Primary Biliary Cirrhosis.

Conditions

  • Primary Biliary Cirrhosis

Interventions

BIOLOGICAL

NGM282

NGM282

Sponsors & Collaborators

  • NGM Biopharmaceuticals Australia Pty Ltd

    collaborator INDUSTRY

  • NGM Biopharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Stephen J Rossi, PharmD · NGM Biopharmaceuticals, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United States
  • Australia
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02135536 on ClinicalTrials.gov